A serious misinterpretation of a consistent inverse association of statin use with glioma across 3 case-control studies

European Journal of Epidemiology

Volumn 32, Issue 1, 2017, Pages 87-88

  Greenland, Sander ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CANCER RISK; CASE CONTROL STUDY; DISEASE ASSOCIATION; GLIOMA; HUMAN; INVERSE ASSOCIATION; LETTER; PRESCRIPTION; BRAIN TUMOR; RISK FACTOR;

BRAIN NEOPLASMS; CASE-CONTROL STUDIES; GLIOMA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK FACTORS;

EID: 85014663151     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-016-0205-z     Document Type: Letter

References (5)

1. Seliger C, Meier CR, Becker C, Jick SS, Bogdahn U, Hau P, Leitzmann MF. Statin use and risk of glioma: population-based case-control analysis. Eur J Epidemiol. 2016;31:947–51.
2. Greenland S, Senn SJ, Rothman KJ, Carlin JC, Poole C, Goodman SN, Altman DG. Statistical tests, confidence intervals, and power: a guide to misinterpretations. Eur J Epidemiol. 2016;31:337–50.
3. Ferris JS, McCoy L, Neugut AI, Wrensch M, Lai R. HMG CoA reductase inhibitors, NSAIDs and risk of glioma. Int J Cancer. 2012;131(6):E1031–7.
4. Gaist D, Andersen L, Hallas J, Sorensen HT, Schroder HD, Friis S. Use of statins and risk of glioma: a nationwide case-control study in Denmark. Br J Cancer. 2013;108(3):715–20.
5. Greenland S, O’Rourke K. Meta-analysis, Ch. 33. In: Rothman KJ, Greenland S, Lash TL, editors. Modern epidemiology. 3rd ed. Philadelphia: Lippincott; 2008. pp. 652–82.